You have bilateral blue-gray or brownish patches on your cheeks that look like melasma, but they never improved with hydroquinone, retinoids, or tranexamic acid. Could it be Hori's nevus, and can laser treatment actually remove these patches without darkening your skin?
Hori's nevus (acquired bilateral nevus of Ota-like macules) and nevus of Ota are forms of dermal melanocytosis—pigment sitting deep in the dermis—which is why topical creams and superficial chemical peels fail to resolve them. The only effective treatments are Q-switched or picosecond lasers (such as the 1064 nm Nd:YAG, 755 nm alexandrite, or 694 nm ruby laser) which deliver photoacoustic energy to fracture deep melanosomes.
In a landmark meta-analysis (Williams 2021, covering 57 studies and 13,417 patients), pooled success rates ranged from 54% to 64% for Q-switched devices and reached up to 100% for picosecond alexandrite lasers. However, the central risk in Fitzpatrick IV-VI skin is post-inflammatory hyperpigmentation (PIH), which ranges from 0% in low-fluence combination protocols to 50% in aggressive high-fluence treatments. Treatment requires 4 to 10+ sessions spaced 4 to 8 weeks apart, costing roughly $500 to $1,250 per session. While recurrence for nevus of Ota is low (0.8% to 2.1%), long-term recurrence data for Hori's nevus specifically remains limited.
What are Hori's nevus and nevus of Ota — and why are they mistaken for melasma?
Both Hori's nevus and nevus of Ota are congenital or acquired pigmentary disorders characterized by active melanocytes residing in the dermis. In normal skin, melanocytes are located exclusively in the basal layer of the epidermis, and any pigment they produce remains superficial. Dermal melanocytosis represents a developmental or migratory arrest of melanocyte precursors during embryogenesis.
The Pathophysiology of Hori's Nevus
Hori's nevus is clinically known as Acquired Bilateral Nevus of Ota-like Macules (ABNOM). First described by Dr. Hori in 1984, it is an acquired condition that typically appears in the third to fifth decades of life. It is most prevalent in East Asian populations, particularly in women (female-to-male ratio is roughly 7:1).
ABNOM presents as bilateral, symmetrical, slate-gray or brownish-blue macules and patches. These patches develop on the malar regions (cheeks), temples, forehead, nose, and eyelids. Unlike nevus of Ota, ABNOM does not involve ocular or mucosal surfaces. The color is distinctive: because the pigment lies deep in the dermis, light passing through the skin undergoes the Tyndall effect. Red light is absorbed, while blue light is scattered back to the observer, giving the patches a classic slate-gray or bluish hue.
The Pathophysiology of Nevus of Ota
Nevus of Ota (oculodermal melanocytosis) is typically congenital (appearing at birth) or develops during early puberty. It presents as a unilateral (one-sided) slate-blue or dark brown patch. It follows the sensory distribution of the ophthalmic (V1) and maxillary (V2) branches of the trigeminal nerve.
Unlike Hori's nevus, nevus of Ota frequently involves the ocular tissues. Up to 60% of patients exhibit hyperpigmentation of the sclera (white of the eye), conjunctiva, cornea, iris, and optic nerve. It can also affect the nasal and oral mucosa. Because of the ocular involvement, nevus of Ota carries a small but life-long risk of glaucoma (due to pigment blocking the trabecular meshwork) and a rare risk of intraocular melanoma. Patients with nevus of Ota require regular ophthalmologic screening.
Why They Are Commonly Misdiagnosed as Melasma
Melasma is a common acquired hypermelanosis presenting as symmetric, brown patches on sun-exposed areas. Because both ABNOM and melasma affect the face of middle-aged women, misdiagnosis is common. However, their physical structures differ:
- Melasma: Primarily epidermal or mixed (epidermal and dermal). The pigment is located superficially.
- Hori's Nevus: Strictly dermal. The abnormal melanocytes are nested in the papillary and middle dermis, surrounded by collagen fibers.
If a provider treats Hori's nevus using standard melasma protocols, such as triple combination creams (hydroquinone, tretinoin, fluocinolone) or oral tranexamic acid, the treatment will fail. Topical molecules cannot penetrate the basement membrane in concentrations high enough to affect deep dermal melanocytes. If you are struggling to manage pigment, read our guide on the best treatment for melasma to understand why topical ladders are reserved for epidermal pigment.
What are the clinical differences between Hori's Nevus, Nevus of Ota, and Melasma?
To help patients and providers navigate these pigmentary conditions, we must distinguish them across several diagnostic criteria:
- Dermatoscopic Features: Under a dermatoscope, ABNOM demonstrates a characteristic pattern of blue-gray dots representing nested dermal melanocytes. Melasma, by contrast, shows a brown network (epidermal) or a pseudonetwork with diffuse brownish-gray pigment (mixed).
- Pigment Distribution: ABNOM appears as discrete macules that gradually coalesce over time, usually localized to the malar region, temples, and alae of the nose. Melasma presents as large, continuous, flat patches with irregular borders, typically in a centrofacial, malar, or mandibular distribution.
- Age of Onset: Nevus of Ota is almost always present at birth or appears in early childhood/puberty. ABNOM is strictly acquired, appearing later in life (typically between ages 25 and 45). Melasma is also acquired, but is highly associated with pregnancy, oral contraceptives, and active sun exposure.
- Histopathological Findings: A biopsy of Hori's nevus reveals bipolar, dendritic melanocytes scattered among normal collagen bundles in the upper and mid-reticular dermis, with no disruption of the overlying epidermis. Melasma biopsy shows increased melanin in the basal layer of the epidermis, with variable dermal melanophages.
Which lasers work, and how many sessions are needed?
Because the target chromophore (melanin) is located deep within the dermis, the laser wavelength must have sufficient penetration depth while sparing the overlying epidermis. Additionally, the laser must deliver its energy in extremely short pulse durations—nanoseconds or picoseconds—to achieve photoacoustic fragmentation.
Laser Wavelength Selection
Three primary laser wavelengths are used to treat dermal melanocytosis:
- 1064 nm Nd:YAG Laser: This is the workhorse wavelength for dark skin types (Fitzpatrick IV-VI). The 1064 nm wavelength penetrates deepest into the dermis and has the lowest absorption in epidermal melanin. This significantly reduces the risk of epidermal burns and post-inflammatory hyperpigmentation. To learn more about Nd:YAG mechanism and tissue depth, read our Nd:YAG laser guide.
- 755 nm Alexandrite Laser: Highly absorbed by melanin. It offers excellent clearance rates, but must be used with caution in darker skin types due to higher epidermal absorption. Picosecond 755 nm devices are widely used for dermal pigment removal.
- 694 nm Ruby Laser: Highly selective for melanin. It provides rapid clearance of blue-gray pigment but has a narrow safety window in Fitzpatrick IV-VI skin. It is primarily used in lighter Fitzpatrick skin types (I-III).
Nanosecond (Q-Switched) vs. Picosecond Technology
- Q-Switched Lasers (Nanosecond): These deliver energy in pulses lasting billionths of a second. They create a mix of photothermal (heat) and photoacoustic (acoustic shockwave) effects. They fracture the dermal melanosomes into large fragments, which are then cleared by macrophages.
- Picosecond Lasers: These deliver energy in pulses lasting trillionths of a second. They generate a purely photoacoustic effect. By fracturing melanin into tiny, dust-like particles, they allow for faster clearance by the lymphatic system. Picosecond devices often require fewer treatment sessions and generate less heat, which is crucial for safety in skin of color. For a comparison of leading picosecond platforms, see our analysis of PicoSure vs PicoWay.
Recommended Session Protocol
- Hori's Nevus: Typically requires 5 to 10+ sessions spaced 4 to 8 weeks apart. Dermal clearance is slow, and initial darkening of the pigment can occur as the fractured melanin is drawn superficially during the macrophage clearance phase.
- Nevus of Ota: Typically requires 4 to 8 sessions spaced 8 to 12 weeks apart. Congenital nevus of Ota in pediatric patients often resolves faster than adult cases because their skin is thinner, allowing better laser penetration.
How effective is treatment — what do the studies actually show?
The clinical literature provides concrete clearance rates and safety margins for Q-switched and picosecond lasers. Let's analyze the key clinical trials and meta-analyses.
The Williams 2021 Meta-Analysis
A comprehensive meta-analysis by Williams et al. published in Lasers in Medical Science (PMID 32839837) evaluated laser treatments for nevus of Ota. The study analyzed data from 57 clinical trials and 13,417 patients to compare efficacy and adverse event rates across wavelengths:
- Q-Switched Nd:YAG (QSNL - 1064 nm):
- Pooled Success Rate: 64% (achieving >75% pigment clearance).
- Adverse Event Rate: 5% (lowest among Q-switched options).
- Q-Switched Ruby Laser (QSRL - 694 nm):
- Pooled Success Rate: 54%.
- Adverse Event Rate: 14% (higher due to strong epidermal melanin absorption).
- Q-Switched Alexandrite Laser (QSAL - 755 nm):
- Pooled Success Rate: 58%.
- Adverse Event Rate: 9%.
- Picosecond Alexandrite Laser (PSAL - 755 nm):
- Pooled Success Rate: 100% (based on limited clinical trials).
- Adverse Event Rate: 44% (highest adverse rate, primarily transient erythema, edema, and petechiae).
This meta-analysis demonstrates that while picosecond devices offer rapid and complete clearance, they are associated with a higher rate of acute skin reactions.
Key Cohort Studies: Kunachak and Huang
Two large cohort studies provide real-world insights into ABNOM/Hori's nevus laser treatment:
- The Kunachak 2000 Series (PMID 10805942):
- Cohort: 70 Asian women with Hori's nevus.
- Protocol: High-fluence Q-switched Nd:YAG (1064 nm) at 8.0 to 10.0 J/cm².
- Clearance: 100% of patients achieved complete clearance after a mean of 2.8 sessions.
- Recurrence: 0% recurrence at a mean follow-up of 42 months.
- Adverse Events: 50% of patients developed temporary post-inflammatory hyperpigmentation. This PIH resolved spontaneously within 2 to 6 months.
- The Huang 2022 Series (PMID 33834379):
- Cohort: 482 Chinese women with Hori's nevus.
- Protocol: Q-switched Alexandrite laser (755 nm).
- Clearance: 53% achieved excellent clearance (>75% reduction); 28% achieved moderate clearance (50% to 75% reduction).
- Adverse Events: 15% developed temporary hyperpigmentation, which resolved within 2 to 6 months.
These cohorts highlight a critical clinical trade-off: high-fluence Q-switched protocols yield rapid, complete clearance but carry a high risk of temporary darkening (PIH). Lower-fluence protocols reduce this risk but require more treatment sessions.
What is the PIH risk in skin of color, and how do protocols reduce it?
In patients with Fitzpatrick IV-VI skin, the main challenge is managing the risk of post-inflammatory hyperpigmentation (PIH). The high energy required to penetrate the dermis can cause thermal damage to the surrounding epidermal melanocytes, triggering reactive melanin synthesis. To understand how to protect dark skin during laser procedures, read our guide on the best laser for dark skin.
Understanding the PIH Risk Window
In darker skin types, the rate of PIH after aggressive Q-switched laser treatments can reach up to 50% (as shown in the Kunachak study). This PIH appears 2 to 4 weeks after the laser session. It presents as a darkening of the treated macules, which can lead patients to believe the treatment has failed.
To manage this risk, researchers have developed low-fluence and combination protocols:
1. Low-Fluence "Laser Toning"
Instead of using high energy to clear pigment in 3 sessions, providers use low-fluence Q-switched Nd:YAG (1064 nm) at energies below 2.0 J/cm² (often 1.2 to 1.6 J/cm²). The laser is passed over the skin in multiple passes. This energy level is sufficient to sublethally damage dermal melanosomes without causing thermal injury to the epidermis. While it requires 10 to 15 sessions, it reduces the PIH rate to under 10%.
2. Combination Laser Protocols (Tian 2015)
A study by Tian et al. published in Dermatologic Surgery (PMC4728905) evaluated a combination of fractional Er:YAG laser resurfacing and low-fluence Q-switched Nd:YAG.
- Mechanism: The fractional Er:YAG creates microscopic thermal zones in the epidermis, encouraging skin turnover and accelerating the elimination of dermal pigment. The low-fluence 1064 nm Nd:YAG targets the deep melanocytes.
- Efficacy: 100% of patients achieved over 80% improvement.
- Safety: 0% of patients developed post-inflammatory hyperpigmentation.
Another study by Ee et al. (PMID 16393596) showed that combining the 532 nm and 1064 nm wavelengths in a single session cleared Hori's nevus faster than using 1064 nm alone, with a manageable safety profile. A systematic review by Kaur (2020) confirmed that combination protocols provide the best efficacy-to-safety ratio in Asian skin.
For a detailed protocol on managing post-procedure pigmentation, refer to our clinical review on post-inflammatory hyperpigmentation.
Post-Laser Recovery and Skincare Optimization
The success of dermal melanocytosis laser treatment relies heavily on the post-treatment recovery protocol. Improper aftercare is the leading cause of persistent PIH and scarring.
Immediate Post-Treatment Care
Directly after a laser session, the treated area will experience mild pinpoint bleeding, redness, and swelling. Providers typically apply a cold compress or cooling gel to reduce the skin temperature.
For the first 48 hours:
- Avoid Friction: Do not scrub the skin. Pat dry gently after washing with a mild cleanser.
- Skip Actives: Discontinue all retinoids, vitamin C, glycolic acid, and salicylic acid.
- Barrier Support: Apply a thin layer of petrolatum or a bland recovery ointment (like Aquaphor or Cicalfate) to protect the skin barrier.
The Pigment Suppression Strategy
To minimize the PIH window, providers frequently prescribe a topical pigment inhibitor to be used between laser sessions. This is called "pigment suppression priming."
- Topical Hydroquinone (2% to 4%): Used to block tyrosinase, the rate-limiting enzyme in melanin synthesis. Typically started 2 weeks before the first session, paused 3 days before, and resumed 1 week post-laser once the skin has re-epithelialized.
- Cysteamine Cream: A non-hydroquinone alternative that reduces melanin index by inhibiting tyrosinase and peroxidase.
- Tranexamic Acid (Topical or Oral): Reduces plasminogen activation, which in turn reduces melanocyte-stimulating hormone (MSH) activity triggered by UV exposure and laser heat.
Sun Protection Policy
Since UV radiation is a powerful stimulator of dermal melanocytosis, strict sun protection is non-negotiable. Patients should use a broad-spectrum, mineral-based sunscreen (zinc oxide or titanium dioxide) with SPF 50+ daily, regardless of the weather. Reapplication every 2 hours when outdoors is mandatory. Physical shielding (wide-brimmed hats, UV umbrellas) is highly recommended.
Does it come back, and why does IPL fail?
Patients considering these treatments often ask two key questions: Will the pigment return after clearance? And can I use Intense Pulsed Light (IPL) as a gentler alternative?
The Recurrence Nuance
There is a common misunderstanding in the literature regarding recurrence:
- Nevus of Ota: Recurrence is rare. Long-term studies show recurrence rates of only 0.8% to 2.1% after complete laser clearance (Lee 2016, PMC5064201). Once cleared, it rarely returns.
- Hori's Nevus (ABNOM): Recurrence is not well-characterized. The Kunachak study reported 0% recurrence at 3.5 years, but most clinical trials monitor patients for only 3 to 6 months post-treatment. Because ABNOM is an acquired condition driven by hormonal factors and sun exposure, long-term recurrence is possible, and patients may require maintenance sessions or strict sun protection.
Why IPL Fails and Can Be Dangerous
Intense Pulsed Light (IPL) is a broadband light source that delivers millisecond pulses. While it is effective for superficial freckles and redness, it is contraindicated for dermal melanocytosis:
- Insufficient Depth: IPL wavelengths are absorbed in the epidermis. The light energy cannot reach the middle dermis in therapeutic concentrations.
- Pulse Duration Issue: Dermal melanosomes have a thermal relaxation time of under 1 microsecond. IPL’s millisecond pulses are too long, causing heat to spill into the surrounding tissue instead of fracturing the pigment.
- High PIH Risk: The broad spectrum of IPL heats the entire epidermal layer. In Fitzpatrick IV-VI skin, this diffuse heating raises the risk of severe epidermal burns and PIH without clearing the deep dermal target.
Using IPL for Hori's nevus or nevus of Ota is an ineffective approach that increases the risk of complications.
Dermal Melanocytosis Treatment Protocols Compared
This table summarizes the treatment options, clinical clearance rates, and safety considerations:
| Treatment Modality | Target Wavelengths | Typical Sessions | Clearance Rate | PIH Risk (Skin of Color) | Best Suited For |
|---|---|---|---|---|---|
| High-Fluence QS Nd:YAG | 1064 nm (nanosecond) | 3 – 5 sessions | Very High (~100% in Kunachak) | Very High (up to 50%) | Patients wanting fast clearance who can tolerate temporary darkening (PIH). |
| Low-Fluence Nd:YAG (Toning) | 1064 nm (nanosecond) | 10 – 15 sessions | Moderate-High (requires patience) | Low (<10%) | Fitzpatrick IV-VI skin; patients seeking to minimize down-time and PIH risk. |
| Picosecond Alexandrite | 755 nm (picosecond) | 4 – 8 sessions | High (up to 100% in Williams) | Moderate-High (~44% AE rate) | Lighter Asian skin types (Fitzpatrick III-IV) seeking rapid clearance. |
| Combination Laser (Fractional + QS) | Er:YAG (2940 nm) + Nd:YAG (1064 nm) | 4 – 8 sessions | Very High (>80% clearance) | Very Low (0% in Tian 2015) | Darker skin types; patients seeking optimal safety and skin texture improvement. |
| IPL / BBL | Broadband (560-1200 nm) | Ineffective | Near 0% | Extreme Risk | Contraindicated. Do not use. |
FAQ: Common questions answered
Is Hori's nevus curable?
Yes, Hori's nevus is curable with laser treatment. Unlike epidermal conditions like melasma, which require lifelong topical management, Q-switched and picosecond lasers can permanently clear the abnormal dermal melanocytes. However, achieving complete clearance requires multiple sessions.
Does Hori's nevus come back after laser treatment?
Recurrence after complete clearance is uncommon but possible. While nevus of Ota has a documented recurrence rate of 0.8% to 2.1%, long-term recurrence data for Hori's nevus is limited. Maintaining strict sun protection and avoiding hormonal triggers can prevent new lesions from forming.
Will laser make the pigmentation darker?
Temporarily, yes. In skin of color, Q-switched and picosecond lasers can trigger post-inflammatory hyperpigmentation (PIH), causing the patches to darken 2 to 4 weeks after treatment. This is a temporary tissue response that resolves with topical bleaching creams and sun protection. Using low-fluence or combination protocols minimizes this risk.
What is the difference between Hori's nevus, nevus of Ota, and melasma?
- Hori's Nevus: Acquired, bilateral slate-gray patches on the cheeks and temples of adults; does not involve the eyes.
- Nevus of Ota: Congenital or pubertal, unilateral dark blue-gray patch following the trigeminal nerve; frequently involves the eye.
- Melasma: Acquired, symmetric brown patches on sun-exposed areas; located superficially in the epidermis.
Do creams or chemical peels work for Hori's nevus?
No. Creams (such as hydroquinone or retinoids) and standard chemical peels only target the epidermis. Because the pigment of Hori's nevus lies deep in the dermis, these topical treatments cannot reach the target cells and will not clear the condition.
Sources
- Williams NM, Gurnani P, Long J, Reynolds J, Pan Y, Suzuki T, Alhetheli GI, Nouri K. Comparing the efficacy and safety of Q-switched and picosecond lasers in the treatment of nevus of Ota: a systematic review and meta-analysis. Lasers in Medical Science. 2021;36(4):723-733. doi:10.1007/s10103-020-03125-9. https://pubmed.ncbi.nlm.nih.gov/32839837/
- Kaur H, et al. Therapeutic options for Hori's nevus: A systematic review. Journal of Cosmetic Dermatology. 2020;19(11):2780-2792. doi:10.1111/jocd.13451. https://pubmed.ncbi.nlm.nih.gov/31714651/
- Kunachak S, Leelaudomlipi P. Q-switched Nd:YAG laser treatment for acquired bilateral nevus of Ota-like maculae: a long-term follow-up. Lasers in Surgery and Medicine. 2000;26(4):376-379. doi:10.1002/(SICI)1096-9101(2000)26:4<376::AID-LSM5>3.0.CO;2-9. https://pubmed.ncbi.nlm.nih.gov/10805942/
- Huang Y, et al. Efficacy and safety of Q-switched alexandrite laser for acquired bilateral nevus of Ota-like macules in 482 Chinese patients. Lasers in Medical Science. 2022;37(4):2145-2152. doi:10.1007/s10103-021-03379-w. https://pubmed.ncbi.nlm.nih.gov/33834379/
- Tian B, et al. Combined fractional Erbium:YAG laser and low-fluence Q-switched Nd:YAG laser for acquired bilateral nevus of Ota-like macules. Dermatologic Surgery. 2015;41(10):1135-1141. doi:10.1097/DSS.0000000000000481. https://pmc.ncbi.nlm.nih.gov/articles/PMC4728905/
- Lee HS, Kim M, Kang HY. Recurrence of Nevus of Ota after successful laser treatment: possible role of dermal stem cells. Annals of Dermatology. 2016;28(5):647-649. doi:10.5021/ad.2016.28.5.647. https://pubmed.ncbi.nlm.nih.gov/27746651/
- Naevus of Ota, Ito and Hori. DermNet NZ. https://dermnetnz.org/topics/naevus-of-ota-ito-hori
- Ee HL, et al. Combined 532 nm and 1064 nm Q-switched Nd:YAG laser therapy for Hori's nevus. Lasers in Surgery and Medicine. 2006;38(1):23-28. doi:10.1002/lsm.20257. https://pubmed.ncbi.nlm.nih.gov/16393596/
